Science1 publisher3 min readPublished
In mouse brown fat, one mitochondrial carrier responds to the clock, cold and dietary fat
University of Copenhagen researchers report in Science that cold raised the mitochondrial carrier SLC25A34 90-fold in mouse brown fat after 24 hours. Because the body clock and dietary fat also control it, the lead author sees a possible new obesity-drug lever in work done so far in mice.
The Scientist · Science desk

What happened
- The carrier surfaced in a search of large mouse brown-fat datasets for proteins that respond to both the clock and cold, alongside the heat-producing protein UCP1.
- Mice lacking specific regulators revealed three controls: REV-ERB alpha holds the gene off during sleep, cold lifts that brake at any hour, and fat switches it on via PPAR alpha.
- Fasting and insulin, the body's signals for burning fat and for storing it, both raised SLC25A34 levels.
- The authors say their biochemical and metabolic data support a model in which the carrier moves oxaloacetate into mitochondria.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- decision Because REV-ERB alpha shuts the gene off during sleep, a drug aimed at this carrier would likely act differently by time of day. Dosing time would be a design question from the start.
- constraint With storage and burning signals both raising the carrier, a drug that boosts it cannot be assumed to steer fat cells only toward burning.
- capability A named cargo, oxaloacetate, gives other labs a specific transport step to test or block when probing brown fat's heat-making fat cycle.
That 90-fold rise starts from almost nothing [7][8]. In mice kept comfortably warm, brown fat holds less SLC25A34 than almost any other organ [7]. After a day in the cold, it holds more than any tissue in the body [8]. The thing the fold change doesn't tell you is how much carrier the tissue makes in absolute terms. The ranking helps: cold moves brown fat from near the bottom of the body's tissues to the top [7][8].
The genetic work is the best part of the design. Mice engineered to lack specific regulatory proteins let the team see which signal stopped moving the gene when a given controller was missing [9]. In the picture that emerged, the clock sets a default schedule and the other inputs override it on demand [9][18]. When cold or a fatty meal creates a need the clock did not anticipate, the authors wrote, "REV-ERB repression is rapidly overridden and PPARs are activated by lipolytic signals to boost SLC25A34 levels" [18]. Once the demand is met, the daily rhythm returns [18]. The authors had framed the puzzle this way: "How thermogenic fat can seamlessly achieve both rhythmic continuity and acute responsiveness is a fundamental question of energy homeostasis that has remained unknown" [17].
The fasting-and-insulin result looks contradictory until you see what active brown fat does with fat. It builds new fat molecules and then burns them, a loop that makes heat and clears fat and sugar from the blood [14]. In that tissue, storing and burning are two halves of one cycle, and the carrier's proposed job is to keep the cycle turning [14][15].
Without the carrier, brown fat cells burned less fuel [16]. The report does not give the size of that drop, and it describes no SLC25A34 measurements in human tissue. The human observation it includes concerns brown fat's daily rhythm: "In mice and humans, BAT metabolic activity begins to increase just before waking, peaks late in the waking period, and then declines to its lowest point during sleep," the authors wrote [5].
"We usually think of the body clock, the response to temperature, and the response to food as separate systems," said Gerhart-Hines, who leads the work at Copenhagen's NNF Center for Basic Metabolic Research and is a co-corresponding author of the Science paper [3][1][2]. He sees a clinical opening where those systems meet [4]. "A mitochondrial transporter that is tuned by the time of day, the temperature, and what we eat raises the possibility of therapies that shift when and how the body burns fuel. That would be a different kind of lever from today's obesity and diabetes treatments," he said [4].
I think the regulatory map is strong mouse physiology [19], and the drug idea is a reasonable hypothesis one step further out. The reported test removes the carrier and watches fuel use fall [16]. A therapy aimed at boosting energy expenditure would have to push the carrier the other way, in human fat [20][16].
What to watch
- Whether raising SLC25A34 activity in mice increases energy expenditure or limits weight gain on a fatty diet, the direction a drug would need.
- Measurements of SLC25A34 in human brown fat, and whether it rises and falls with the daily rhythm the authors describe in people.
- Independent transport assays confirming oxaloacetate as the carrier's cargo.